Choosing the right timing for interval debulking surgery and perioperative chemotherapy may improve the prognosis of advanced epithelial ovarian cancer: a retrospective study
Open Access
- 27 March 2021
- journal article
- research article
- Published by Springer Nature in Journal of Ovarian Research
- Vol. 14 (1) , 1-9
Abstract
Background: Primary debulking surgery (PDS) is the main treatment for patients with advanced ovarian cancer, and neoadjuvant chemotherapy (NACT) is for bulky stage III-IV patients who are poor surgical candidates and/or for whom there is a low likelihood of optimal cytoreduction. NACT can increase the rate of complete cytoreduction, but this advantage has not translated to an improvement in survival. Therefore, we aimed to identify factors associated with the survival of patients who received NACT followed by interval debulking surgery (IDS). Methods: A retrospective study was conducted in FIGO stage IIIC-IV epithelial ovarian cancer patients who underwent PDS or IDS in our center between January 1st, 2013, and December 31st, 2018. Results: A total of 273 cases were included, of whom 20 were lost to follow-up. Progression-free survival (PFS) and overall survival (OS) of the IDS and PDS groups were found to be similar, although the proportion of patients in stage IV and serum carbohydrate antigen 125 (CA125) levels before treatment in the IDS group were significantly higher than that in the PDS group. Body mass index (BMI), CA125 level before IDS, residual disease after surgery, and the interval between preoperative and postoperative chemotherapy were all found to be independent prognostic factors for PFS; FIGO stage, residual disease after surgery, and CA125 level before IDS were independent prognostic factors for OS. We found that PFS and OS were both significantly longer in patients with normal CA125 levels before IDS and when the interval between preoperative and postoperative chemotherapy was < 35.5 days (IDS-3 group) than for patients in the PDS group. Conclusions: The results suggested the importance of timely IDS and postoperative chemotherapy and potentially allowed the identification of patients who would benefit the most from NACT. Normal CA125 levels before IDS and an interval between preoperative and postoperative chemotherapy no longer than 5 weeks were associated with improved prognosis in advanced ovarian cancer patients.Keywords
This publication has 25 references indexed in Scilit:
- Primary Debulking Surgery Versus Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian CancerAmerican Journal of Clinical Oncology, 2018
- Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancerArchives of Gynecology and Obstetrics, 2015
- Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trialThe Lancet, 2015
- Is it possible to define an optimal time for chemotherapy after surgery for ovarian cancer?Gynecologic Oncology, 2014
- Obesity and epithelial ovarian cancer survival: a systematic review and meta-analysisJournal of Ovarian Research, 2014
- Does neoadjuvant chemotherapy impair long-term survival for ovarian cancer patients? A nationwide Danish studyGynecologic Oncology, 2014
- The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma — Analysis of patient data in the prospective OVCAD studyGynecologic Oncology, 2013
- Neoadjuvant chemotherapy in advanced ovarian cancer: On what do we agree and disagree?Gynecologic Oncology, 2013
- Height, weight, BMI and ovarian cancer survivalGynecologic Oncology, 2012
- Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian CancerNew England Journal of Medicine, 2010